Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Disease analysis > Oncology > Breast and gynecological cancer

Breast and gynecological cancer


show blocks helper
loader
  • Sort by Default
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Disease Analysis: Ovarian Cancer

    Read More

    Ovarian cancer is defined as a group of tumors that originate in the ovaries. Epithelial ovarian cancer is the prevailing cause of death from gynecological malignancies in the Western world.

    November 17, 2020
    Find out more
  • Market Spotlight: Uterine Cancer

    $1,318.00

    This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    October 21, 2020
    Find out more
  • Disease Analysis: HR+/HER2- Breast Cancer

    Read More

    Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is defined by the overexpression of estrogen or progesterone receptors, or both, and a lack of HER2 expression.

    October 9, 2020
    Find out more
  • Disease Analysis: Triple-Negative Breast Cancer

    Read More

    TNBC is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors, and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.

    September 15, 2020
    Find out more
  • HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

    $2,995.00

    Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence

    October 16, 2018
    Find out more
  • Breast cancer: HER2 Positive Forecast and Market Analysis to 2025

    Read More

    The approval of Herceptin (trastuzumab) in 1998 transformed the treatment of this aggressive disease, leading to increased disease-free progression and survival outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer.

    May 9, 2018
    Find out more
  • Cervical Cancer Disease Coverage Forecast and Market Analysis to 2024

    Read More

    Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix.

    June 7, 2017
    Find out more
Page 1 of 1
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.
By continuing to use the website, you consent to our use of cookies.
OkRead more
Scroll to top